Change in the Management of Neurotune AG
Neurotune AG announced a change in the management. Starting March 1st 2009, Dr. Bruno Oesch will take over the position of Chief Executive Officer from Dr. Andreas J. Schulze, who joined Neurotune in 2005 and is holding the position of CEO since 2006. Andreas J. Schulze will leave at his request to take on a fresh challenge in another company shortly.
Bruno Oesch is co-founder of Prionics AG and Neurotune AG. Serving as Chairman of the Board of Directors since Neurotune's foundation in 2005 he has been significantly involved in the strategic alignment of the company.
Most read news
Organizations
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Scientists find a brake that acts when cellular motors run too far - Cell-organisation better understood

BIOTECH AUSTRIA calls for better framework conditions for the biotechnology sector of the future - Proposals provide impetus for research, infrastructure and investments in Austria

LUMiSizer | Nanoparticle analyzers | LUM
Antitope and Synthon announce collaboration
Analysis by AlgoNomics reveals that Anticalins have an immunogenicity level comparable to the wild-type human lipocalin
Cellectis Acquires Vectocell Technology to Accelerate Therapeutic Development Programs
New data for Menveo vaccine show excellent immune response and broad protection for infants against meningococcal meningitis - Menveo (MenACWY-CRM) the first quadrivalent conjugated meningitis vaccine to demonstrate an excellent immune response in infants
Kentucky Bioprocessing, Icon Genetics and Mapp Biopharmaceutical have entered into discussions to merge their businesses
